Synergistic antitumor activity of a self-assembling camptothecin and capecitabine hybrid prodrug for improved efficacy

Journal of Controlled Release

Volumn 263, Issue , 2017, Pages 102-111

  Ma, Wang ^a   Su, Hao ^b   Cheetham, Andrew G ^b   Zhang, Weifang ^a   Wang, Yuzhu ^b   Kan, QuanCheng ^a   Cui, Honggang ^a,b,c,d  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Camptothecin; Capecitabine; Chemotherapy; Drug conjugate; Drug delivery

Indexed keywords

CELL CULTURE; CHEMICAL STABILITY; CHEMOTHERAPY; DRUG DELIVERY; DRUG PRODUCTS; NANOSTRUCTURES; TARGETED DRUG DELIVERY;

ANTI-TUMOR ACTIVITIES; CAMPTOTHECIN (CPT); CAPECITABINE; COMBINATION CHEMOTHERAPY; DRUG-CONJUGATES; MORPHOLOGICAL TRANSFORMATIONS; STRUCTURAL STABILITIES; THERAPEUTIC OUTCOMES;

CONTROLLED DRUG DELIVERY;

CAMPTOTHECIN; CAPECITABINE; NANOCARRIER; PEPTIDE; PRODRUG; SUP35 PEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; NANOMATERIAL;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BETA SHEET; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESOPHAGEAL ADENOCARCINOMA CELL LINE; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG RELEASE; HUMAN; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CAPECITABINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG LIBERATION; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; PRODRUGS;

EID: 85009755012     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.01.015     Document Type: Article

References (74)

1. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
2. Petros, R.A., DeSimone, J.M., Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9 (2010), 615–627.
3. Brannon-Peppas, L., Blanchette, J.O., Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 64 (2012), 206–212.
4. Brigger, I., Dubernet, C., Couvreur, P., Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 64 (2012), 24–36.
5. Miele, E., Spinelli, G.P., Miele, E., Tomao, F., Tomao, S., Albumin-bound formulation of paclitaxel (Abraxane (R) ABI-007) in the treatment of breast cancer. Int. J. Nanomedicine 4 (2009), 99–105.
6. Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132 (2008), 171–183.
7. Harries, M., Ellis, P., Harper, P., Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23 (2005), 7768–7771.
8. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., O'Shaughnessy, J., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005), 7794–7803.
9. Stirland, D.L., Nichols, J.W., Miura, S., Bae, Y.H., Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J. Control. Release 172 (2013), 1045–1064.
10. Grodzinski, P., Farrell, D., Future opportunities in cancer nanotechnology-NCI strategic workshop report. Cancer Res. 74 (2014), 1307–1310.
11. Kamaly, N., Xiao, Z.Y., Valencia, P.M., Radovic-Moreno, A.F., Farokhzad, O.C., Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41 (2012), 2971–3010.
12. Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P., Blakey, D.C., Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73 (2013), 2412–2417.
13. Venditto, V.J., Szoka, F.C., Cancer nanomedicines: so many papers and so few drugs!. Adv. Drug Deliv. Rev. 65 (2013), 80–88.
14. Duncan, R., Gaspar, R., Nanomedicine(s) under the microscope. Mol. Pharm. 8 (2011), 2101–2141.
15. Su, H., Koo, J.M., Cui, H., One-component nanomedicine. J. Control. Release 219 (2015), 383–395.
16. Huang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., Yan, D., Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy. J. Am. Chem. Soc. 136 (2014), 11748–11756.
17. Kataoka, K., Harada, A., Nagasaki, Y., Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 64 (2012), 37–48.
18. Kwon, G.S., Kataoka, K., Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 64 (2012), 237–245.
19. MacKay, J.A., Chen, M.N., McDaniel, J.R., Liu, W.G., Simnick, A.J., Chilkoti, A., Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater. 8 (2009), 993–999.
20. Desmaele, D., Gref, R., Couvreur, P., Squalenoylation: a generic platform for nanoparticular drug delivery. J. Control. Release 161 (2012), 609–618.
21. Coburn, J.M., Kaplan, D.L., Engineering biomaterial-drug conjugates for local and sustained chemotherapeutic delivery. Bioconjug. Chem. 26 (2015), 1212–1223.
22. Tan, X.Y., Li, B.B., Lu, X.G., Jia, F., Santori, C., Menon, P., Li, H., Zhang, B.H., Zhao, J.J., Zhang, K., Light-triggered, self-immolative nucleic acid-drug nanostructures. J. Am. Chem. Soc. 137 (2015), 6112–6115.
23. Tong, R., Cheng, J.J., Anticancer polymeric nanomedicines. Polym. Rev. 47 (2007), 345–381.
24. Zhao, F., Ma, M.L., Xu, B., Molecular hydrogels of therapeutic agents. Chem. Soc. Rev. 38 (2009), 883–891.
25. Tong, R., Cheng, J.J., Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. Angew. Chem. Int. Ed. 47 (2008), 4830–4834.
26. Tong, R., Cheng, J.J., Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles. J. Am. Chem. Soc. 131 (2009), 4744–4754.
27. Gao, Y., Kuang, Y., Guo, Z.F., Guo, Z.H., Krauss, I.J., Xu, B., Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative. J. Am. Chem. Soc. 131 (2009), 13576–13577.
28. Cheetham, A.G., Zhang, P., Lin, Y.A., Lin, R., Cui, H., Synthesis and self-assembly of a mikto-arm star dual drug amphiphile containing both paclitaxel and camptothecin. J. Mater. Chem. B 2 (2014), 7316–7326.
29. Cheetham, A.G., Zhang, P.C., Lin, Y.A., Lock, L.L., Cui, H., Supramolecular nanostructures formed by anticancer drug assembly. J. Am. Chem. Soc. 135 (2013), 2907–2910.
30. Lin, R., Cheetham, A.G., Zhang, P.C., Lin, Y.A., Cui, H., Supramolecular filaments containing a fixed 41% paclitaxel loading. Chem. Commun. 49 (2013), 4968–4970.
31. Lin, Y.A., Cheetham, A.G., Zhang, P.C., Ou, Y.C., Li, Y.G., Liu, G.S., Hermida-Merino, D., Hamley, I.W., Cui, H., Multiwalled nanotubes formed by catanionic mixtures of drug amphiphiles. ACS Nano 8 (2014), 12690–12700.
32. Ma, W., Cheetham, A.G., Cui, H., Building nanostructures with drugs. Nano Today 11 (2016), 13–30.
33. Lin, R., Cui, H., Supramolecular nanostructures as drug carriers. Curr. Opin. Chem. Eng. 7 (2015), 75–83.
34. Cheetham, A.G., Keith, D., Zhang, P.C., Lin, R., Su, H., Cui, H., Targeting tumors with small molecule peptides. Curr. Cancer Drug Targets 16 (2016), 489–508.
35. Zhang, P.C., Lock, L.L., Cheetham, A.G., Cui, H., Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment. Mol. Pharm. 11 (2014), 964–973.
36. Wang, Y., Cheetham, A.G., Angacian, G., Su, H., Xie, L., Cui, H., Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv. Drug Deliv. Rev., 2016, 10.1016/j.addr.2016.06.015.
37. Su, H., Zhang, P.C., Cheetham, A.G., Koo, J.M., Lin, R., Masood, A., Schiapparelli, P., Quinones-Hinojosa, A., Cui, H., Supramolecular crafting of self-assembling camptothecin prodrugs with enhanced efficacy against primary cancer cells. Theranostics 6 (2016), 1065–1074.
38. Cheetham, A.G., Ou, Y.C., Zhang, P.C., Cui, H., Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles. Chem. Commun. 50 (2014), 6039–6042.
39. Greco, F., Vicent, M.J., Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61 (2009), 1203–1213.
40. Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6 (2006), 789–802.
41. Yim, K.L., Cunningham, D., Optimizing irinotecan regimens for colorectal cancer. Nat. Rev. Clin. Oncol. 6 (2009), 560–561.
42. Walko, C.M., Lindley, C., Capecitabine: a review. Clin. Ther. 27 (2005), 23–44.
43. Longley, D.B., Harkin, D.P., Johnston, P.G., 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3 (2003), 330–338.
44. Malet-Martino, M., Martino, R., Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7 (2002), 288–323.
45. Napier, K.J., Scheerer, M., Misra, S., Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J. Gastrointest. Oncol. 6 (2014), 112–120.
46. Schweigert, M., Dubecz, A., Stein, H.J., Oesophageal cancer-an overview. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 230–244.
47. Ilson, D.H., Esophageal cancer chemotherapy: recent advances. Gastrointest. Cancer Res. 2 (2008), 85–92.
48. Wiedmann, M.W., Mossner, J., New and emerging combination therapies for esophageal cancer. Cancer Manag. Res. 5 (2013), 133–146.
49. Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., Andre, T., Gornet, J.M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P.L., Boucher, E., Rebischung, C., Hammel, P., Rougier, P., Bedenne, L., Bouche, O., Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a french intergroup (federation francophone de cancerologie digestive, federation nationale des centres de lutte contre le cancer, and groupe cooperateur multidisciplinaire en oncologie) study. J Clin Oncol 32 (2014), 3520–3526.
50. Hamley, I.W., Peptide fibrillization. Angew. Chem. Int. Ed. 46 (2007), 8128–8147.
51. Nelson, R., Sawaya, M.R., Balbirnie, M., Madsen, A.O., Riekel, C., Grothe, R., Eisenberg, D., Structure of the cross-beta spine of amyloid-like fibrils. Nature 435 (2005), 773–778.
52. Dubikovskaya, E.A., Thorne, S.H., Pillow, T.H., Contag, C.H., Wender, P.A., Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 12128–12133.
53. Estrela, J.M., Ortega, A., Obrador, E., Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43 (2006), 143–181.
54. Lee, M.H., Yang, Z., Lim, C.W., Lee, Y.H., Dongbang, S., Kang, C., Kim, J.S., Disulfide-cleavage-triggered chemosensors and their biological applications. Chem. Rev. 113 (2013), 5071–5109.
55. Liu, J.Y., Liu, W.E., Weitzhandler, I., Bhattacharyya, J., Li, X.H., Wang, J., Qi, Y.Z., Bhattacharjee, S., Chilkoti, A., Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. Angew. Chem. Int. Ed. 54 (2015), 1002–1006.
56. Wang, H., Tang, L., Tu, C.L., Song, Z.Y., Yin, Q., Yin, L.C., Zhang, Z.H., Cheng, J.J., Redox-responsive, core-cross-linked micelles capable of on-demand, concurrent drug release and structure disassembly. Biomacromolecules 14 (2013), 3706–3712.
57. Cavalli, S., Albericio, F., Kros, A., Amphiphilic peptides and their cross-disciplinary role as building blocks for nanoscience. Chem. Soc. Rev. 39 (2010), 241–263.
58. Versluis, F., Marsden, H.R., Kros, A., Power struggles in peptide-amphiphile nanostructures. Chem. Soc. Rev. 39 (2010), 3434–3444.
59. Aida, T., Meijer, E.W., Stupp, S.I., Functional supramolecular polymers. Science 335 (2012), 813–817.
60. Fleury, F., Ianoul, A., Berjot, M., Feofanov, A., Alix, A.J.P., Nabiev, I., Camptothecin-binding site in human serum albumin and protein transformations induced by drug binding. FEBS Lett. 411 (1997), 215–220.
61. Fleury, F., Kudelina, I., Nabiev, I., Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. FEBS Lett. 406 (1997), 151–156.
62. Cui, H., Webber, M.J., Stupp, S.I., Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Biopolymers 94 (2010), 1–18.
63. Haines-Butterick, L., Rajagopal, K., Branco, M., Salick, D., Rughani, R., Pilarz, M., Lamm, M.S., Pochan, D.J., Schneider, J.P., Controlling hydrogelation kinetics by peptide design for three-dimensional encapsulation and injectable delivery of cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 7791–7796.
64. Meijer, J.T., Henckens, M.J.A.G., Minten, I.J., Lowik, D.W.P.M., van Hest, J.C.M., Disassembling peptide-based fibres by switching the hydrophobic-hydrophilic balance. Soft Matter 3 (2007), 1135–1137.
65. Meijer, J.T., Roeters, M., Viola, V., Lowik, D.W., Vriend, G., van Hest, J.C., Stabilization of peptide fibrils by hydrophobic interaction. Langmuir 23 (2007), 2058–2063.
66. Hu, M.X., Huang, P., Wang, Y., Su, Y., Zhou, L.Z., Zhu, X.Y., Yan, D.Y., Synergistic combination chemotherapy of camptothecin and floxuridine through self-assembly of amphiphilic drug-drug conjugate. Bioconjug. Chem. 26 (2015), 2497–2506.
67. Mans, D.R.A., Grivicich, I., Peters, G.J., Schwartsmann, G., Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur. J. Cancer 35 (1999), 1851–1861.
68. Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Jarvinen, T., Savolainen, J., Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7 (2008), 255–270.
69. Lock, L.L., Reyes, C.D., Zhang, P.C., Cui, H., Tuning cellular uptake of molecular probes by rational design of their assembly into supramolecular nanoprobes. J. Am. Chem. Soc. 138 (2016), 3533–3540.
70. Chou, T.C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22 (1984), 27–55.
71. Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2010), 440–446.
72. Azrak, R.G., Cao, S., Slocum, H.K., Toth, K., Durrani, F.A., Yin, M.B., Pendyala, L., Zhang, W.H., McLeod, H.L., Rustum, Y.M., Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin. Cancer Res. 10 (2004), 1121–1129.
73. Nagano, T., Yasunaga, M., Goto, K., Kenmotsu, H., Koga, Y., Kuroda, J., Nishimura, Y., Sugino, T., Nishiwaki, Y., Matsumura, Y., Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. Int. J. Cancer 127 (2010), 2699–2706.
74. Caudle, K.E., Thorn, C.F., Klein, T.E., Swen, J.J., McLeod, H.L., Diasio, R.B., Schwab, M., Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94 (2013), 640–645.